Common new active substance approvals across major regulatory authorities (multi-year total) vs Novel active substance launches

Common new active substance approvals across major regulatory authorities (multi-year total) and Novel active substance launches worldwide, compared over time.

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.

Common new active substance approvals across major regulatory authorities (multi-year total) and Novel active substance launches

Unit: count · 4 observations

2 series · one axis
Common new active substance approvals across major regulatory authorities (multi-year total) and Novel active substance launches: GlobalCommon new active substance approvals across major regulatory authorities (multi-year total) and Novel active substance launches. 2 indicators on one axis: Common new active substance approvals across major regulatory authorities (multi-year total), Novel active substance launches. 4 observations from 2004–2023 to 2025, ranging from 37 to 942. Latest values: Common new active substance approvals across major regulatory authorities (multi-year total) 52 (2021–2025); Novel active substance launches 79 (2025). 0 200 400 600 800 1,000 2004 2008 2012 2016 2020 2024 52 79 Common new active substance approvals across major regulatory authorities (multi-year total) Novel active substance launches
Common new active substance approvals across major regulatory authorities (multi-year total) and Novel active substance launches: GlobalCommon new active substance approvals across major regulatory authorities (multi-year total) and Novel active substance launches. 2 indicators on one axis: Common new active substance approvals across major regulatory authorities (multi-year total), Novel active substance launches. 4 observations from 2004–2023 to 2025, ranging from 37 to 942. Latest values: Common new active substance approvals across major regulatory authorities (multi-year total) 52 (2021–2025); Novel active substance launches 79 (2025). 0 300 600 900 1,200 2004 2008 2012 2016 2020 2024 52 79 Common new active substance approvals across major regulatory authorities (multi-year total) Novel active substance launches
Common new active substance approvals across major regulatory authorities (multi-year total) and Novel active substance launches: GlobalCommon new active substance approvals across major regulatory authorities (multi-year total) and Novel active substance launches. 2 indicators on one axis: Common new active substance approvals across major regulatory authorities (multi-year total), Novel active substance launches. 4 observations from 2004–2023 to 2025, ranging from 37 to 942. Latest values: Common new active substance approvals across major regulatory authorities (multi-year total) 52 (2021–2025); Novel active substance launches 79 (2025). 0 300 600 900 1,200 2004 2008 2012 2016 2020 2024 52 79 Common new active substance approvals across major regulatory authorities (multi-year total) Novel active substance launches
View the underlying data
Common new active substance approvals across major regulatory authorities (multi-year total) and Novel active substance launches: Global
Indicator Period Type Value
Common new active substance approvals across major regulatory authorities (multi-year total) 2021–2025 Actual 52
Common new active substance approvals across major regulatory authorities (multi-year total) 2016–2020 Actual 37
Novel active substance launches 2025 Actual 79
Novel active substance launches 2004–2023 Actual 942

Provenance

Where these numbers come from

Common new active substance approvals across major regulatory authorities (multi-year total)

Total count of new active substances approved across all designated major regulatory authorities during the period.

2 observations in Global · source organisations: CIRS

Novel active substance launches

Total number of novel active substances launched.

2 observations in Global · source organisations: IFPMA, IQVIA

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related